| 6.275 0.915 (17.07%) | 11-28 13:01 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 7.44  |
1-year : | 8.69 |
| Resists | First : | 6.36 |
Second : | 7.44 |
| Pivot price | 4.63 |
|||
| Supports | First : | 4.81 |
Second : | 3.85 |
| MAs | MA(5) : | 5.38 |
MA(20) : | 4.5 |
| MA(100) : | 3.49 |
MA(250) : | 3.08 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 92  |
D(3) : | 93.4 |
| RSI | RSI(14): 84.4 |
|||
| 52-week | High : | 6.36 | Low : | 1.88 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ SVRA ] has closed above the upper band by 16.1%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 252.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 5.49 - 5.51 | 5.51 - 5.53 |
| Low: | 5.03 - 5.06 | 5.06 - 5.08 |
| Close: | 5.31 - 5.36 | 5.36 - 5.39 |
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
Sat, 29 Nov 2025
Savara Inc. Sees Price Target Raised Amid Promising Drug Developments - StocksToTrade
Sat, 29 Nov 2025
Savara (NASDAQ:SVRA) Sees Strong Trading Volume - Here's Why - MarketBeat
Fri, 28 Nov 2025
Savara Inc. (SVRA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Tue, 25 Nov 2025
Bronstein, Gewirtz & Grossman, LLC Encourages Savara Inc. (SVRA) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Tue, 25 Nov 2025
Securities Lawsuit Alert: Savara Inc. (SVRA) - Contact Levi & Korsinsky Before November 7, 2025 - The National Law Review
Thu, 20 Nov 2025
Savara Announces Participation in Upcoming Investor Healthcare Conferences - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 203 (M) |
| Shares Float | 130 (M) |
| Held by Insiders | 4.6 (%) |
| Held by Institutions | 83.5 (%) |
| Shares Short | 17,800 (K) |
| Shares Short P.Month | 13,770 (K) |
| EPS | -0.53 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.44 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -39.7 % |
| Return on Equity (ttm) | -78.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.42 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.6 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -99 (M) |
| Levered Free Cash Flow | -55 (M) |
| PE Ratio | -11.84 |
| PEG Ratio | 0 |
| Price to Book value | 13.94 |
| Price to Sales | 0 |
| Price to Cash Flow | -12.87 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|